Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 3/20 | 0.33 |
| ▸ | XPNPEP1 | Q9NQW7 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168271 | 1.00 | PEPD (0.33) | PEPDXPNPEP1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL21168270 | 0.96 | PEPD (0.33) | PEPDXPNPEP1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL21168339 | 0.94 | PEPD (0.33) | PEPDXPNPEP1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL21168341 | 0.94 | PEPD (0.33) | PEPDXPNPEP1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL21168500 | 0.92 | PEPD (0.33) | PEPDXPNPEP1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL25476845 | 0.87 | VSIR (0.31) | DPP4F2 | |
| SCHEMBL25476870 | 0.86 | F2 (0.32) | DPP4F2 | |
| SCHEMBL25476843 | 0.86 | ACE (0.32) | DPP4F2 | |
| SCHEMBL21168293 | 0.86 | BMP1 (0.31) | DPP4 | |
| SCHEMBL21168320 | 0.86 | ACE (0.36) | DPP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2021-05-13 | — | — | US | disclosed |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | CD47, HIF1AN, PIK3R5 | PEPD 4850/4885XPNPEP1 2956/4885LMNA 2788/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | PEPD 4838/4885XPNPEP1 3023/4885LMNA 3055/4885 |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | PEPD 4838/4885XPNPEP1 3023/4885LMNA 3055/4885 |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | CD47, HIF1AN, PIK3R5 | PEPD 4836/4885XPNPEP1 3013/4885LMNA 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.